Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ArriVent BioPharma, Inc. filings document a Nasdaq-listed clinical-stage oncology company with common stock registered under the Exchange Act. Its Form 8-K reports cover financial results, Regulation FD disclosures, clinical and preclinical program announcements, conference presentations, IND-related updates, material-event disclosures, and exhibits tied to press releases.
Proxy materials describe stockholder voting matters, board elections, auditor ratification, annual meeting procedures, and governance information. The filing record also reflects capital-structure disclosures, emerging growth company status, material agreements, and risk-oriented disclosures associated with ArriVent's firmonertinib program and antibody-drug conjugate pipeline.
ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and α-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).
At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of ≥30%—the study’s threshold for overall response—occurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded ≥30% tumor reduction, underscoring central-nervous-system activity.
Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.
Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed “filed” for Exchange Act purposes.
ArriVent BioPharma (NASDAQ:AVBP) submitted a routine Form 4 on 28 June 2025 reporting an insider transaction by director Merdad Parsey.
According to the filing, Parsey acquired 15,502 non-qualified stock options on 18 June 2025 at an exercise price of $24.89 per share. The options become exercisable on 18 June 2026 and expire on 17 June 2035. No common shares were sold or purchased outright, and the transaction was reported as direct ownership. After the grant, Parsey holds an additional 15,502 derivative securities linked to AVBP common stock.
No other material changes, sales, or new share ownership percentages were disclosed in this filing.
Form 4 filing reveals that Kristine Peterson, Director at ArriVent BioPharma, was granted 15,502 non-qualified stock options on June 18, 2025. The options have the following key terms:
- Exercise price set at $24.89 per share
- Exercisable starting June 18, 2026
- Expiration date of June 17, 2035
- Underlying security is ArriVent BioPharma common stock
The options were acquired at a price of $0.00, indicating a compensation grant. The filing was signed by James Kastenmayer as attorney-in-fact for Peterson on June 20, 2025. This equity compensation aligns the director's interests with shareholders through long-term stock ownership potential.
ArriVent BioPharma director John Hohneker received a non-qualified stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 15,502 stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Total cost basis of $0.00 as this was a compensation grant
The transaction was reported via Form 4 filing and executed through attorney-in-fact James Kastenmayer. This equity-based compensation aligns the director's interests with shareholders and represents a standard component of non-employee director compensation.
ArriVent BioPharma director Chris Nolet received a new stock option grant on June 18, 2025. The transaction details include:
- Granted 15,502 non-qualified stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Zero cost basis for the options grant
This Form 4 filing, signed by James Kastenmayer as attorney-in-fact, represents a standard director compensation equity grant. The options provide Nolet with long-term alignment with shareholder interests through a 10-year exercise window, subject to a one-year vesting requirement.